T-Balance Therapeutics – a new way to unlock the potential of an innovative antibody
T-Balance Therapeutics is a young start-up company that is developing a monoclonal antibody with the aim of exploiting the potential of this molecule in inflammatory diseases. The company recently opened a location in the Potsdam Science Park. The small, international team of scientists and physicians with solid expertise in all major areas of drug development works successfully on questions of the balance of the immune system.
Crucial for this are regulatory T cells, on which the antibody selectively exerts an activating effect. Regulatory T cells have a central function in the immune system by generating self-tolerance to their own tissue and tolerance to harmless substances such as pollen. In addition, they make a significant contribution to actively regulating an inflammatory reaction.
Examples of diseases in which regulatory T cells play a role are allergic asthma and various autoimmune diseases.
In the one and a half years since its founding, T-Balance Therapeutics has already managed to bring the antibody into a clinical phase IIa study in the indication allergic asthma.
“We are proud to have received ERDF funding and a loan from the Investment Bank of the State of Brandenburg for our project,” explains Managing Director Dr. Cathrin Schleussner. “We have been represented in the Potsdam Science Park since November 2020. The Startup Space at GO:IN is an ideal location to find the right partners for the further development of the antibody. To this end, we plan to cooperate with local companies and scientific institutes. We also benefit from the fertile ground of an open, communicative environment, as we find in the Science Park together with many other startup companies.”